Since Genova settled in Changzhou high-tech Zone, Jiangsu Province in 2015, it has overcome difficulties, forged ahead, made every effort to build a technical platform and production platform with the world's leading prokaryotic Epro genetic engineering as the core, focused on the development of ...
Two EU clinical late-stage biosimilar assets. Since China joined ICH in 2017, the regulatory policies and registration requirements have been updated to adopt FDA/EMA’s guidance and review standards, supporting Genova to advance co-registration in both EU and China The EU clinical trial of one ...